Study: Improvements in transplant education did not increase organ transplants healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Aptabio s Isuzinaxib (APX-115) proves its effect on a key kidney function marker in a Phase 2 clinical study in patients with diabetes and chronic kidney.
Tricida Inc. (TCDA) is priced at $11.80 after the most recent trading session. At the very opening of the session, the stock price was $12.46 and reached a high price of $12.7599, prior to closing the session it reached the value of $12.28. The stock touched a low price of $11.53.Recently in News on
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Tricida, Inc. (Nasdaq: TCDA) announced today that a late-breaking clinical trial abstract on the Phase 3, VALOR-CKD renal outcomes trial has been selected by the American Society of Nephrology (ASN) and the Kidney Week Education Committee for oral presentation in the Hig.
Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight Potential Value of TAVNEOS™ (avacopan) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.